Citius Pharma(CTXR) - 2025 Q4 - Annual Results

Financial Performance - Citius Pharmaceuticals reported a net loss of $39.7 million, or $3.38 per share, for the fiscal year ended September 30, 2025, compared to a net loss of $40.2 million, or $5.97 per share, for the previous year[6]. - Net loss for 2025 was $(39,740,269), slightly higher than $(39,425,839) in 2024[15]. - Stock-based compensation decreased to $10,836,291 from $11,839,678 year-over-year[15]. - Net cash used in operating activities improved to $(26,552,738) from $(28,201,375) in the previous year[15]. - Net cash used in investing activities increased to $(5,750,000) from $(5,000,000) in 2024[15]. - Net proceeds from common stock offerings rose significantly to $32,303,148 compared to $13,803,684 in 2024[15]. - Cash and cash equivalents stood at $4.3 million as of September 30, 2025, compared to $3.3 million in the previous year[6]. - Cash and cash equivalents at the end of 2025 were $4,252,290, up from $3,251,880 in 2024[15]. - Inventory changes resulted in a significant increase in cash outflow of $(12,649,207) compared to $(2,133,871) in 2024[15]. - Accounts payable increased to $8,766,481 from $1,999,877 year-over-year, indicating improved supplier financing[15]. - Operating lease right-of-use asset and liability recorded was $786,697, reflecting new lease agreements[15]. - Interest paid in 2025 was $187,389, indicating ongoing financing costs[15]. Research and Development - Research and development expenses decreased to $9.2 million for the fiscal year 2025, down from $11.9 million in 2024, while general and administrative expenses slightly increased to $18.5 million from $18.2 million[6]. - Citius is actively engaging with the FDA to advance Mino-Lok and explore additional indications and markets for LYMPHIR[2]. Product Launch and Market Access - Citius Oncology launched LYMPHIR™, a novel immunotherapy for cutaneous T-cell lymphoma, in December 2025, with an estimated initial market exceeding $400 million[3][5]. - Citius secured access to LYMPHIR in 19 international markets through regional distribution partners, allowing access under named patient programs[3]. - The company executed service agreements with three leading U.S. pharmaceutical wholesalers to distribute LYMPHIR throughout the U.S.[3]. - Citius ensured production and sufficient supply of LYMPHIR for up to 18 months of estimated commercial demand[3]. Assets and Financial Position - The total assets of Citius Pharmaceuticals increased to $130.9 million as of September 30, 2025, compared to $116.7 million in 2024[11].